Lymphoid neoplasms encompass a heterogeneous group of malignancies with a predilection for immunocompromised individuals, and the disease burden of lymphoid neoplasms has been rising globally over the last decade. At the same time, mounting studies delineated a crucial role of the gut microbiome in the aetiopathogenesis of various diseases. Orchestrated interactions between myriad microorganisms and the gastrointestinal mucosa establish a defensive barrier for a range of physiological processes, especially immunity and metabolism. These findings provide new perspectives to harness our knowledge of the gut microbiota for preclinical and clinical studies of lymphoma. Here, we review recent findings that support a role for the gut microbiota in the development of lymphoid neoplasms and pinpoint relevant molecular mechanisms. Accordingly, we propose the microbiota-gut-lymphoma axis as a promising target for clinical translation, including auxiliary diagnosis, novel prevention and treatment strategies, and predicting clinical outcomes and treatment-related adverse effects of the disease in the future. This review will reveal a fascinating avenue of research in the microbiota-mediated lymphoma field.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216388PMC
http://dx.doi.org/10.1177/11795549211024197DOI Listing

Publication Analysis

Top Keywords

lymphoid neoplasms
16
gut microbiome
8
role gut
8
gut microbiota
8
emerging roles
4
gut
4
roles gut
4
lymphoid
4
microbiome lymphoid
4
neoplasms
4

Similar Publications

Deciphering the Differences Between Epstein-Barr Virus-Associated and Negative Gastric Cancer in the Prospect of CDKN2A Genomic Alterations and Lymphoid Infiltration.

Cancer Med

January 2025

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Sir Y.K. Pao Cancer Center, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.

Background: Gastric cancer (GC) is a major health concern worldwide. One important contributing factor is the presence of the Epstein-Barr virus (EBV). However, the molecular pattern of how EBV participates in the malignant transition process remains unclear.

View Article and Find Full Text PDF

Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer.

J Transl Med

January 2025

Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, Heilongjiang, 150001, People's Republic of China.

Background: Although the TNM staging system plays a critical role in guiding adjuvant chemotherapy for colorectal cancer (CRC), its precision for risk stratification in stage II and III CRC patients with proficient DNA mismatch repair (pMMR) remains limited. Therefore, precise predictive models and research on postoperative treatments are crucial for enhancing patient survival and improving quality of life.

Methods: This retrospective study analyzed 1051 pMMR CRC patients who underwent radical resection and were randomly assigned to training (n = 736) and validation (n = 315) groups.

View Article and Find Full Text PDF

Clinical analysis of pulmonary mucosa-associated lymphoid tissue lymphoma coexisting with lung cancer.

BMC Cancer

January 2025

Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

Background: Primary pulmonary Mucosa-associated lymphoid tissue (MALT) lymphoma is a sporadic disease with a favorable prognosis. Particularly, pulmonary MALT lymphoma coexisting with lung cancer is not only rare but also prone to misdiagnosis. The clinical characteristics and prognostic factors of this co-occurrence, however, remain poorly understood.

View Article and Find Full Text PDF

Gastric cancer is a common malignant tumor of the digestive tract, and its treatment remains a significant challenge. In recent years, the role of various immune cells in the tumor microenvironment in cancer progression and treatment has gained increasing attention. Immunotherapy, primarily based on immune checkpoint inhibitors, has notably improved the prognosis of patients with gastric cancer; however, challenges regarding therapeutic efficacy persist.

View Article and Find Full Text PDF

Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in lung adenocarcinoma.

Immunol Res

January 2025

Respiratory and Critical Care Medicine Center, Renmin Hospital, Hubei University of Medicine, No. 39, Chaoyang Middle Road, Shiyan City, Hubei Province, China.

The presence of tertiary lymphoid structures (TLSs) has been correlated with improved prognosis and clinical outcomes in response to immunotherapy in certain solid tumors. However, the precise role of TLSs in lung adenocarcinoma (LUAD) remains unclear. Four datasets of LUAD were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!